Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 11;14(3):360-371.
doi: 10.3390/idr14030040.

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations

Andrea Marino  1   2 , Antonio Munafò  3 , Egle Augello  3 , Carlo Maria Bellanca  3 , Carmelo Bonomo  1 , Manuela Ceccarelli  2 , Nicolò Musso  1 , Giuseppina Cantarella  3 , Bruno Cacopardo  2 , Renato Bernardini  3   4
Affiliations
Review

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations

Andrea Marino et al. Infect Dis Rep. .

Abstract

Two years have passed since WHO declared a pandemic state for SARS-CoV-2 infection. COVID-19 pathogenesis consists of a first viral phase responsible for early symptoms followed by an inflammatory phase, cytokine-mediated, responsible for late-onset manifestations up to ARDS. The dysregulated immune response has an outstanding role in the progression of pulmonary damage in COVID-19. IL-6, through the induction of pro-inflammatory chemokines and cytokines, plays a key role in the development and maintenance of inflammation, acting as a pioneer of the hyperinflammatory condition and cytokine storm in severe COVID-19. Therefore, drugs targeting both IL-6 and IL-6 receptors have been evaluated in order to blunt the abnormal SARS-CoV-2-induced cytokine release. Sarilumab, a high-affinity anti-IL-6 receptor antibody, may represent a promising weapon to treat the fearsome hyperinflammatory phase by improving the outcome of patients with moderate-to-severe COVID-19 pneumonia. Further prospective and well-designed clinical studies with larger sample sizes and long-term follow-up are needed to assess the efficacy and the safety of this therapeutic approach to achieve improved outcomes in COVID-19.

Keywords: COVID-19; IL-6; IL-6R; cytokines; sarilumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The potential role of IL-6 receptor antagonization by sarilumab in SARS-CoV-2-induced cytokine release syndrome (CRS)-like syndrome. After SARS-CoV-2 infection, immune cells release cytokines, including IL-6. IL-6 can either attach to its respective membrane-bound receptor (mIL-6R) or soluble receptor (sIL-6R), which activates JAK/STAT pathways. The different signaling modalities, including cis-signaling, trans-signaling, and trans-presentation are reported. Abbreviations: gp130, glycoprotein 130; IL-6, interleukin-6; JAK, Janus family tyrosine kinase; mIL-6R, membrane-bound interleukin-6 receptor; sIL-6R, soluble interleukin-6 receptor; STAT, signal transducer and activator of transcription; P, phosphoryl group. Illustrations use elements from Servier Medical Art (https://smart.servier.com/, accessed on 10 April 2022).
See this image and copyright information in PMC

References

    1. Mehta O.P., Bhandari P., Raut A., Kacimi S.E.O., Huy N.T. Coronavirus Disease (COVID-19): Comprehensive Review of Clinical Presentation. Front. Public Health. 2021;8:1034. doi: 10.3389/fpubh.2020.582932. - DOI - PMC - PubMed
    1. Ministero Della Salute COVID-19—Situazione in Italia, su. [(accessed on 8 May 2022)]; Available online: www.salute.gov.it.
    1. Grasselli G., Tonetti T., Protti A., Langer T., Girardis M., Bellani G., Laffey J., Carrafiello G., Carsana L., Rizzuto C., et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: A multicentre prospective observational study. Lancet Respir. Med. 2020;8:1201–1208. doi: 10.1016/S2213-2600(20)30370-2. - DOI - PMC - PubMed
    1. Osuchowski M.F., Winkler M.S., Skirecki T., Cajander S., Shankar-Hari M., Lachmann G., Monneret G., Venet F., Bauer M., Brunkhorst F.M., et al. The COVID-19 puzzle: Deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir. Med. 2021;9:622–642. doi: 10.1016/S2213-2600(21)00218-6. - DOI - PMC - PubMed
    1. Marino A., Pampaloni A., Scuderi D., Cosentino F., Moscatt V., Ceccarelli M., Gussio M., Celesia B., Bruno R., Borraccino S., et al. High-flow nasal cannula oxygenation and tocilizumab administration in patients critically ill with COVID-19: A report of three cases and a literature review. World Acad. Sci. J. 2020;2:23. doi: 10.3892/wasj.2020.64. - DOI

LinkOut - more resources